Dzień dobry,



W naszej firmie Pharmabest Sp. z o. o. nieustająco dążymy do zapewnienia jak najlepszej ochrony danych osobowych, które nam przekazujesz. Zależy nam również, aby informacje dotyczące sposobu, w jaki je wykorzystujemy i przetwarzamy były dla Ciebie jasne i zrozumiałe.


Dlatego też wprowadzamy nową politykę prywatności, która spełnia oba te założenia, a jednocześnie realizuje wymogi Rozporządzenia o Ochronie Danych Osobowych (RODO).


Nowa Polityka prywatności będzie obowiązywała w pełni od dnia 25 maja 2018 r. Możesz już teraz zapoznać się z jej treścią [tutaj], do czego serdecznie Cię zachęcamy.


RODO: Unijne rozporządzenie dotyczące ochrony danych osobowych - Rozporządzenie Parlamentu Europejskiego i Rady (UE) 2016/679 z dnia 27 kwietnia 2016 r. w sprawie ochrony osób fizycznych w związku z przetwarzaniem danych osobowych i w sprawie swobodnego przepływu takich danych oraz uchylenia dyrektywy 95/46/WE, które zacznie obowiązywać z dniem 25 maja 2018 r.



Pozdrawiamy,
Zespół Pharmabest sp. z o.o.

Vivomixx® – oryginalne artykuły naukowe

171) Morampudi V., Dalwadi U., Bhinder G., Sham HP., Gill SK., Chan J., Bergstrom KS., Huang T., Ma C., Jacobson K., Gibson DL., Vallance BA. The goblet cell-derived mediator RELM-β drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. Mucosal Immunol. 2016 Jan 27. doi: 10.1038/mi.2015.140

 

170) Manuzak JA, Hensley-McBain T., Zevin AS., Miller C., Cubas R., Agricola B., Gile J., Richert-Spuhler L., Patilea G., Estes JD., Langevin S., Reeves RK., Haddad EK., Klatt NR. Enhancement of Microbiota in Healthy Macaques Results in Beneficial Modulation of Mucosal and Systemic Immune Function. J Immunol. 2016 Jan 29. doi:10.4049/jimmunol.1502470

 

169) Selwyn F., Cheng S., Klaassen C., Cui J. Regulation of Hepatic Drug-Metabolizing Enzymes in  Germ-Free Mice by Conventionalization and ProbioticsDrug Metab Dispos 44:262–274, February 2016

 

168)  Dolpady J., Sorini C., Di Pietro C., Caputo A., Ferrarese R., Saita D., De Simone C., Clementi M., Canducci F., Falcone M..Oral probiotic VSL#3 prevents T1D by modulating microbiota and inducing a Indoleamine 2,3-dioxygenase (IDO)-enriched tolerogenic intestinal environment. Journal of Diabetes Research Volume 2016 (2016), Article ID 7569431, 12 pages. (2016)

 

167) Do EJ, Hwang SW, Kim SY, Ryu YM, Cho EA, Chung EJ, Park S, Lee HJ, Byeon JS, Ye BD, Yang DH, Park SH, Yang SK, Kim JH, Myung SJ. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by Balsalazide and VSL#3. J Gastroenterol Hepatol. 2015 Dec 29. doi: 10.1111/jgh.13280

 

166) Boutagy NE., Neilson AP., Osterberg KL., Smithson AT., Englund TR., Davy BM., Hulver MW., Davy KP. Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet. Obesity (Silver Spring). 2015 Oct 14. doi: 10.1002/oby.21212 (2015)

 

165) Osterberg KL.,2, Boutagy NE., McMillan RP., Stevens JR., Frisard MI., Kavanaugh JW., Davy BM., Davy KP., Hulver MW. Probiotic supplementation attenuates increases in body mass and fat mass during high-fat diet in healthy young adults. Obesity (Silver Spring). 2015 Oct 14. doi: 10.1002/oby.21230. (2015)

 

164) Brown K., Godovannyi A., Ma C., Zhang Y., Ahmadi-Vand Z., Dai C., Gorzelak MA., Chan Y., Chan JM., Lochner A., Dutz JP., Vallance BA., Gibson DL. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. ISME J. 2015 Aug 14. doi: 10.1038/ismej.2015.114.

 

163) D’Mello C., Ronaghan N., Zaheer R.,  Dicay M., Le T., MacNaughton W., Surrette M., Swain M. Probiotics Improve Inflammation-Associated Sickness Behavior by Altering Communication between the Peripheral Immune System and the Brain.  The Journal of Neuroscience, 29 July 2015, 35(30): 10821-10830 (2015)

 

162) Sinha A., Gupta S., Chellani H., Maliye C., Kumari V., Arya S., Garg BS.,  Gaur S., Gaind R., Deotale V., Taywade M., Prasad MS., Thavraj V., Mukherjee A., Roy M. Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial. BMJ Open 2015;5:e006564 doi:10.1136/bmjopen-2014-006564 (2015)

 

161) Man AL., Bertelli E., Rentini S., Regoli M., Briars G., Marini M., Watson AJ., Nicoletti C. Age-associated modifications of intestinal permeability and innate immunity in human small intestine. Clin Sci (Lond). 2015 Oct;129 (7):515-27

 

160) Mariman R., Tielen F., Koning F., Nagelkerken L..The Probiotic Mixture VSL#3 Has Differential Effects on Intestinal Immune Parameters in Healthy Female BALB/c and C57BL/6 Mice. J Nutr. 2015 Jun;145(6):1354-61. (2015)

 

159) Miccheli A., Capuani G., Marini F., Tomassini A., Praticò G., Ceccarelli S., Gnani D., Baviera G., Alisi A. Putignani L., Nobili V. Urinary H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatmentInternational Journal of Obesity, 1–8 doi:10.1038/ijo.2015.40 (2015)

 

158) Mastromarino P., Capobianco D. Miccheli A., Praticò G., Campagna G., Laforgia N., Capursi T.,  Baldassarre E. Administration of a multistrain probiotic product (VSL#3) to women in the perinatal period differentially affects breast milk beneficial microbiota in relation to mode of delivery. Pharmacological Research 95-96 (2015) 63-70

 

157) Talero E. , Bolivar S., Román J. Alcaide A. Fiorucci S. Motilva V. Inhibition of Chronic Ulcerative Colitis-associated Adenocarcinoma Development in Mice by VSL#3. Inflamm Bowel Dis 0:1–11 (2015).

 

156) Souza D., Senchenkova E., Russell J., Granger D. MyD88 Mediates the Protective Effects of Probiotics Against the Arteriolar Thrombosis and Leukocyte Recruitment Associated with Experimental Colitis. Inflamm Bowel Dis. 0:1-13 (2015)

 

155)  Kim S., Choi S., Park K., Park M., Shin J., Lee T., Jung K., Koo H., Myung S., and Constipation Research group of Korean Society of Neurogastroenterology and Motility. Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation. J Neurogastroenterol Motil,  J Neurogastroenterol Motil,  21(1): 111-120 (2015)

 

154) Rohatgi S., Ahuja V., Makharia G., Rai T., Das P., Dattagupta S., Mishra V., Garg S. VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial. BMJ Open Gastro; 2015 Feb 9;2(1):e000018. (2015)

 

153) Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM,Enns R, Bitton A, Chiba N, Paré P, Rostom A, Marshall J, Depew W, Bernstein CN, Panaccione R,Aumais G, Steinhart AH, Cockeram A, Bailey RJ, Gionchetti P, Wong C, Madsen K. The Probiotic VSL#3 has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence Following Surgery for Crohn’s Disease. Clin Gastroenterol Hepatol. May;13(5):928-35.e2. doi: 10.1016/j.cgh.2014.10.031. (2015)

 

152) Valentini L., Pinto A., Bourdel-Marchasson I., Ostan R., Brigidi P., Turroni S., Hrelia S., Hrelia P., Bereswill S., Fischer A., Leoncini E., Malaguti M., Blanc-Bisson C., Durrieu J., Spazzafumo L., Buccolini F., Pryen F., Donini LM., Franceschi C., Lochs H. Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota – The “RISTOMED project”: Randomized controlled trial in healthy older people. Clin Nutr.  Aug;34(4):593-602. doi: 10.1016/j.clnu.2014.09.023 (2015)

 

151) Mariman R., Tielen F., Koning F., Nagelkerken L. The Probiotic mixture VSL#3 dampens LPS- Induced Chemokine Expression in Human Dendritic Cells by Inhibition of STAT-1PhosphorylationPlos One Dec 29;9(12):e115676. doi:10.1371/journal.pone.0115676 (2014)

 

150) Samanta A., Mandal A., Patra A., Mandal S., Roy S., Pradhan S., Das K., and Nandi D. Impact of Probiotic supplementation on intestinal microflora of rat under environmental hypobaric pressure. Int.J.Curr.Microbiol.App.Sci (2014) 3(8) 282-291

 

149) Sanaie S., Mameghani M., Hamishehkar H., Mojtahedzadeh M., Mahmoodpoor A. Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial.  J Res Med Sci. 19(9): 827-833 (2014)

 

148) Mouli P.  Benjamin J, Singh B., Mani K, Garg SK, Saraya A, Joshi YK. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy- a non-inferiority randomized controlled trial. Hepatol Res. 2014 Sep 29. doi: 10.1111/hepr.12429.

 

147) Distrutti E., O’Reilly J., McDonald C.,, Cipriani S., Renga B., Lynch M, Fiorucci S. Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP. PLoS One.  Sep 9;9(9) DOI: 10.1371/journal.pone.0106503 (2014)

 

146) Mariman R., Kremer B., Koning F., Nagelkerken L. The probiotic mixture VSL#3 mediates both pro- and anti-inflammatory responses in bone marrow-derived dendritic cells from C57BL/6 and BALB/c mice. Br J Nutr. 2014 Sep 2:1-10.

 

145) Dhiman R., Rana B., Agrawal S., Garg A., Chopra M., Thumburu K., Khattri A., Malhotra S.,  Duseja A., Chawla Y.  Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients with Cirrhosis: a Randomized, Controlled Trial. Gastroenterology 147:1327–1337 (2014)

 

144) Mar J, Nagalingam N, Song Y, Onizawa M, Lee JW, Lynch S. Amelioration of DSS-induced murine colitis by VSL#3 supplementation is primarily associated with changes in ileal microbiota composition. Gut Microbes. 5(4) 1-10 Aug. (2014)

 

143) Wong R., Yang C., Song C., Wong J., Ho K. Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study. Dig Dis Sci DOI 10.1007/s10620-014-3299-8 (2014)

 

142) Vicari E., La Vignera S., Castiglione R., Condorelli R.,   Vicari L.,  Aldo E Calogero. Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3. Asian J Androl 16, 735-739  (2014)

 

141)  Isidro R., Bonilla F., Pagan H., Cruz M., Lopez P., Godoy L., Hernandez S.,  Loucil-Alicea R.,  Rivera-Amill V., Yamamura Y. Isidro A., Appleyard C. The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner. J Clin Cell Immunol  Volume 5 • Issue 3 (2014)

 

140) Rashid S.,  Khodja N. Auger C., Alhosin M., Boehm N., Mammosser M., Schini-Kerth V. Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System. Plos One May 2014 | Volume 9 | Issue 5 | e97458 (2014)

 

139) Rajkumar H.,  Mahmood N., Kumar M., Varikuti S., Challa H., Myakala SEffect of Probiotic (VSL#3) and Omega-3 on Lipid Profile, Insulin Sensitivity, Inflammatory Markers, and Gut Colonization in Overweight Adults: A Randomized, Controlled Trial. Mediators of Inflammation Volume  Article ID 348959, p. 8 (2014)

 

138) Sánchez  E., Nieto JC., Boullosa A., Vidal S., Sancho FJ., Rossi G., Sancho-Bru P., Oms R., Mirelis B., Juárez C., Guarner C., Soriano G. VSL#3 Probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver Int. 2014 Apr 22. doi: 10.1111/liv.12566.

 

137) Alisi A., Bedogni G., Baviera G., Giorgio V., Porro E., Paris C., Giammaria P., Reali L., Anania F., Nobili V. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 16 APR 2014 DOI: 10.1111/apt.12758 (2014)

 

136) Rossi G, Pengo G, Caldin M, Palumbo Piccionello A, Steiner JM, Cohen ND, Jergens AE, Suchodolski JS. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. PLoS One. 2014 Apr 10;9(4):e94699. doi: 10.1371/journal.pone.0094699. eCollection (2014)

 

135) Rincón D., Vaquero J., Hernando A., Galindo E., Ripoll C., Puerto M., Salcedo M., Francés R., Matilla A., Catalina M., Clemente G., Such J., Bañares R. Oral Probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascitesLiver International doi: 10.1111/liv.12539 April (2014)

 

134) De Girolamo C. Rainaldi S., Bovenga F. Murzilli S. Moschetta A. Microbiota Modification with Probiotics Induces Hepatic Bile Acid Synthesis via Downregulation of the Fxr-Fgf15 Axis in Mice. Cell Reports 7, 1–7, April 10, (2014)

 

133) Rubio-del-Campo A., M. Coll-Marques J., Yebra M., Buesa J., Perez-Martinez G., Monedero V., Rodriguez-Diaz J. Noroviral P-Particles as an In Vitro Model to Assess the Interactions of Noroviruses with Probiotics. Plos One February Vol 9, Issue 2, 9(2): e89586 (2014)

 

132) Sang L., Chang B., Dai C, Gao N., Liu W.,Jiang M. Heat-killed VSL#3 Ameliorates Dextran Sulfate Sodium (DSS)-Induced Acute Experimental Colitis in Rats. Int. J. Mol. Sci. 2014, 15, 15-28.

 

131) Pellino G., Sciaudone G., Candilio G.,  Camerlingo A., Marcellinaro R., De Fatico S., Rocco F.,  Canonico S., Riegler G., Selvaggi F.Early postoperative administration of probiotics versus placebo in elderly patients undergoing elective colorectal surgery: a double-blind randomized controlled trial. BMC Surgery 2013, 13(Suppl 2):S57

 

130) Salim S.Y., Young P.Y., Lukowski C.M., Madsen K.L., Sis B., Churchill T.A., Khadaroo R.G. VSL#3 probiotics provide protection against acute intestinal ischemia perfusion injury. Beneficial Microbes 2013 Dec 1;4(4):357-65. doi: 10.3920/BM2013.0026.

 

129) Lunia K., Sharma B., Sharma P., Sachdeva S., Srivastava S. Probiotics Prevent Hepatic Encephalopathy in Patients with Cirrhosis: a Randomized Controlled TrialClinical Gastroenterology and Hepatology (2013), doi: 10.1016/j.cgh.2013.11.006.

 

128) Liang S., Webb T., Li Z.  Probiotics Antigens Stimulate Hepatic NKT cells. Immunology Feb;141(2):203-10. doi: 10.1111/imm.12180 (2014)

 

127) Mameghani M., Sanaie S., Mahmoodpoor A., Hamishehkar H. Effect of a probiotic preparation (VSL#3) in critically ill patients: A randomized, double-blind, placebo-controlled trial (Pilot Study). Pak J Med Sci 2013;29(2):490-494.

 

126) Chang B., Sang L., Wang Y., Tong J.,  Zhang D., Wang B. The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury. BMC Gastroenterology Oct 20;13(1):1–1. (2013)

 

125) Sanaie S., Mameghani M., Mahmoodpoor A., Kamran S., Samad E. Effect of a Probiotic Preparation (VSL#3) on CardiovascularRisk Parameters in Critically-Ill Patients. Journal of Cardiovascular and Thoracic Research, 2013, 5(2), 67-70 doi: 10.5681/jcvtr.2013.014

 

124) Arthur J., Gharaibeh R., Uronis J., Perez-Chanona E., Sha W., Tomkovich S., Muhlbauer M., Fodor A., Jobin C. VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer. Scientific Reports DOI: 10.1038/srep02868 Sept  (2013)

 

123) Jayakumar S., Carbonneau M., Hotte N., Befus A., St. Laurent C., Owen R., McCarthy M., Madsen K., Bailey R., Ma M., Bain V., Rioux  K., Tandon P. VSL#3 probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver International, Aug 23;33(10):1–8 (2013)

 

122) Barletta B., Rossi G.,Schiavi E., Butteroni C., Corinti Silvia, Boirivant M., Di Felice G. Probiotic VSL#3-induced TGF-β ameliorates food allergy inflammation in a mouse model of peanut sensitization through the induction of regulatory T cells in the gut mucosa. Mol. Nutr. Food Res. 2013, 00, 1–12

 

121) Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial Metabolic Effects of a Probiotic via Butyrate-induced GLP-1 Hormone Secretion. J Biol Chem. 2013 Aug 30;288(35):25088–97

 

120) Ng S., Lam E., Lam T., Chan Y., Law W., Tse P., Kamm M., Sung J., Chan F., Wu J. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndromeJournal of Gastroenterology and Hepatology 28 1624-1631 June (2013).

 

119) Distrutti E., Cipriani S., Mencarelli A., Renga B., Fiorucci S. Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndromePlos One Vol 8, Issue 5, e63893, May (2013)

 

118) Gupta N., Kumar A., Sharma P., Garg V., Sharma B., Sarin S. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver International  Sep;33(8):1148–57. (2013)

 

117) Selinger C.P., Bell A. Cairns A., Lockett M., Sebastian S., Haslam N. Probiotic VSL#3 prevents probiotic – associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. Journal of Hospital Infection June 84 (2) : 259 – 265 (2013)

 

116) Facchinetti F., Dante G., Pedretti I., Resasco P., Annessi E., Dodero D. The role of oral probiotic for bacterial vaginosis in pregnant women. A pilot study. Minerva Ginecologica. Vol. 65 n. 2 Apr. 65 (2) : 215-221 (2013)

 

115) Dharmani P., De Simone C., Chadee K. The probiotic mixture VSL#3 accelerates gastric ulcer healing by stimulating vascular endothelial growth factorPlos One Vol 8, Issue 3 e58671, March (2013)

 

114) Hörmannsperger G., Von Schillde M.A., Haller D. Lactocepin as a protective microbial structure in the context of IBD. Gut Microbes. 4:2, 1-6; March/April (2013)

 

113) Klatt N,. Canary L., et Al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV – infected macaquesJ Clin. Investigation. Doi: 10.1172/JCI66227 (2013)

 

112) Dai C., Zheng CQ., Meng FJ., Zhou Z., Sang LX., Jiang M. VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis. Mol Cell Biochem. Feb 374(1-2) :1-11.(2013)

 

111) Arsland H., Sarpinar aksu D., Terzi G., Nisbet C., Therapeutic effects of probiotic bacteria in parvoviral enteritis in dogs. Revue Méd. Vét. 163, 2, 55-59 (2012)

 

110) Zhang H., Yu L., Yang W., Tang L., Lin Y., Wu H., Zhai B., Tan Y., Shan L., Liu Q., Chen H., Dai R.,  Qiu, He Y.,Wang C., Zheng L., Qiong Li Y.,Quan Wu F., Li Z., Yan H., Wang H. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. Journal of Hepatology (2012) vol. 57 j 803–812 (+ supplement data)

 

109) Dai C., Zhao DH., Jiang M. VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. International Journal of Molecular Medicine 29: 202-208. DOI: 10.3892/ijmm.2011.839 (2012)

 

108) Thang CL, Boye JI, Zhao X. Low Doses of Allergen and Probiotic Supplementation Separately or in Combination Alleviate Allergic Reactions to Cow β-Lactoglobulin in Mice. J Nutr. Dec 12 (2012)

 

107) Vitali B., Cruciani F., Baldassarre M.E., Capursi T., Spisni E., Valerii M.C., Candela M., Turroni S., Brigidi P. Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion. BMC Microbiology  2012,  12:236

 

106) Mencarelli A., Cipriani S., Renga B., Bruno A., D’Amore C., Distrutti E., Fiorucci S. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. Plos one Vol. 7 Issue 9 (2012)

 

105) Lee J., Moon G., Kwon H., Jung W., Seo P., Baec T., Kim H. Effect of a probiotic preparation (VSL#3) in patients with mild to moderate ulcerative colitis. Korean J Gastroeterol Vol. 60 n. 2 94-101 (2012)

 

104) Campeau J.L., Salim S.Y. Albert E.J., Hotte N., Madsen K.L. Intestinal epithelial cells modulate antigen-presenting cell responses to bacterial DNA. Infect. Immun. 2012, 80 (8): 2632. DOI: 10.1128/IAI. 00288-12.

 

103) Corridoni D., Pastorelli L., Mattioli B., Locovei S., Ishikawa D., Arseneau K., Chieppa M., Cominelli F., Pizarro T. Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by TNF- dependent mechanism. Plos One 2012, 7 (7): e42067.

 

102) Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No TherapyAmerican Journal of Gastroenterology  2012 Jul;107(7):1043-50

 

101) Stephens J.H. and Hewett P.J. Clinical trial assessing VSL#3 for the treatment of anterior resection syndromeANZ Journal of Surgery  2012 Jun, 82(6):420-7

 

100) Rosania R., Minenna M., Giorgio F., Faciorusso A., De Francesco V., Hassan C., Panella C., Ierardi E. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics : a placebo – controlled study. Inflammation & Allergy – Drug Targets, 11, 244-249 (2012)

 

99) Von Schillde M.A., Hörmannsperger G., Weiher M., Alpert C.A., Hahne H., Bäuerl  C., Van Huynegem K., Steidler L., Hrncir T., Pérez-Martinez G., Kuster B., Haller D. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host & Microbe, 387-396 (2012).

 

98) Bassaganya-Riera J., Viladomiu M., Pedragosa M., De Simone C., Hontecillas R. Immunoregolatory mechanism underlying prevention of colitis – associated colorectal cancer by probiotic bacteria. Plos One  April, Vol 7, Issue 4 (2012)

 

97) Rehman A. et Al. Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestineBMC Microbiology  12:47 (2012)

 

96) Bassaganya-Riera J., Viladomiu M., Pedragosa M., De Simone C., Carbo A., Shayhutdinov R., Jobin C., Arthur J., Corl B., Vogel H., Storr M., Hontecillas R.  Probiotic Bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis. Plos One   February Vol.7, Issue 2 (2012)

 

95) Dai C., Guandalini S., Zhao D.-H., Jiang M. Antinociceptive effect of VSL#3 on visceral hypersensivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function. Molecular and cellular Biochemistry 362:43-53 (2012)

 

94) Gad M., Ravn P., Soborg D., Lund-Jensen K., Ouwehand A., Jensen S. Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria. FEMS Immunol Med Microbiol DOI: 10.1111/j.1574-695x.2011.00835.x (2011)

 

93) Tursi A., Elisei W., Brandimarte G., Giorgetti GM., Inchingolo C., Nenna R., Ierardi E., Tumour necrosis factor-alpha expression in segmental colitis associated with diverticulosis down-regulates after treatment. J Gastrointestin Liver Dis,  Vol. 20 n.4 365-370 (2011)

 

92) Mariman R., Kremer B., Van Erk M., Lagerweij T., Koning F., Nagelkerken L., Gene expression profiling identifies mechanism of protection to recurrent trinitrobenzene sulforic acid colitis mediated by probiotics. Inflammatory Bowel Disease  DOI: 10.1002/ibd.22849 (2011)

 

91) Mittal Vibhu Vibhas, Sharma Barjesh Chander, Sharma Praveen, Sarin Shiv Kumar. A randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology & Hepatology, Aug;23(8):725–32 (2011)

 

90) Appleyard CB, Cruz ML, Isidro AA, Arthur JC, Jobin C, De Simone C. Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancerAm J Physiol Gastrintest Liver Physiol.  301(6):G1004-13 (2011)

 

89) Ismail Al-Wahsh, Yan Wu, Michael Liebman. Acute probiotics ingestion reduces gastrointestinal oxalate absorption in healthy subjectsUrol Res DOI 10.1007/s00240-011-0421-7 (2011)

 

88) Mencarelli A., Palladino G., Renga B., D’Amore C., Cipriani S., Distrutti E. and Fiorucci S.,Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. Plos one 7:e22978 (2011)

 

87) Michail S. and Kenche H. Gut Microbiota is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome  Probiotics & Antimicro. Prot. 3:1-7 (2011)

 

86) Angulo S., Danese S., Morales A., Llacuna L., Masamunt :M.C., Pultz N., Cifone M.G., DeSimone C., Delgado S.,  Vila G., Panes D., donskey C., Fernandez-Checa J.C., Fiocchi C. and Sans M.  Probiotics selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase  Plos One  6:e16953 (2011)

 

85) Friederich P., Verschuur J., van Heumen B.W.H., Roelofs H.M.J., Berkhout M., Nagtegaal I.D., van Oijen M.G.H.,. van Krieken Johannes, Peters W.H.M. and Nagengast F.M. Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis Int J Colorectal Dis26:575-82 (2011)

 

84) Zaharoni H., Rimon E., Vardi H., Friger M., Bolotin A., Shahar D., Probiotics improve bowel movements in hospitalized elderly patients –The PROAGE study J Nutr Health Aging. 15:215-20  (2011)

 

83) Schiavi E., Barletta B., Butteroni C., Corinti S., Boirivant M. e Di Felice G., Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy Allergy  66: 499–508 (2011)

 

82) Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, Cruz ML, Appleyard CB, Jobin C. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitisInflamm Bowel Dis. 17:289-97 (2010)

 

81) Aumeunier A., Grela F., Ramadan A., Pham Van L., Bardel E., Alcala A., Jeannin P., Akira S., Bach J-F., Thieblemont N., Systemic Toll-like Receptor Stimulation Suppresses Experimental Allergic Asthma and Autoimmune Diabetes in NOD Mice. Plos one. 5(7):e11484 (2010)

 

80) Hörmannsperger G, Clavel T, Hoffmann M, Reiff C, Kelly D, Loh G, Blaut M, Hölzlwimmer G, Haller D. Posttranslational Inhibition of Proinflammatory Chemokine Secretion in Intestinal Epithelial Cells: Implications for Specific IBD Indications. J Clin Gastroenterol44 :S10-5. (2010)

 

79) Tursi A., Brandimarte G., Papa A., Giglio A., Elisei W., Giorgetti GM, Forti G., Morini S., Hassan C., Pistoia MA.,  Modeo ME, Rodino S., D ’ Amico T., Sebkova L., Sacca N., Di Giulio E., Luzza F., Imeneo M., Larussa T., Di Rosa S., Annese V., Danese S. and Gasbarrini A. Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL # 3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study Am J Gastroenterol.105:2218-27 (2010)

 

78) Guandalini S, Magazzù G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, Sibal A, Romano C, Canani RB, Lionetti P, Setty M VSL#3 Improves Symptoms in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Crossover Study. J Pediatr Gastroenterol Nutr. 51:24-34 (2010)

 

77) Montalto M., Gallo A., Curigliano V., D’Onofrio F., Santoro L., Covino S., Dalvai S., Gasbarrini A. and Gasparrini G. The effects of a probiotic mixture on NSAID enteropathy: a randomized, double-blind, cross-over, placebo-controlled studyAliment Pharmacol Ther32:209-214 (2010)

 

76) Ng S.C., Plamondon S., Kamm M.A., Hart A.L., Al-Hassi H.O., Guenther T., Stagg A.J. Knight S.C. Immunosuppressive Effects via Human Intestinal Dendritic Cells of Probiotic Bacteria and Steroids in the Treatment of Acute Ulcerative Colitis Inflamm Bowel Dis. 16:1286-98 (2010)

 

75) Okombo J. and Liebman M. Probiotic-induced reduction of gastrointestinal oxalate absorption in healthy subjects. Urol Res 38:169-178 (2010)

 

74) Frohmader Terence J., Chaboyer Wendy P., Robertson Iain K. and Gowardman John Patients Given the Multispecies Probiotic VSL#3: A Pilot Trial Decrease in Frequency of Liquid Stool in Enterally Fed Critically Ill Am J Crit Care 19: 1-11 (2010)

 

73)  Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. PNAS  107:454-459 (2010)

 

72) Turroni S., Vitali B., Candela M., Gionchetti P., Rizzello F., Campieri M., Brigidi P. Antibiotics and probiotics in chronic pouchitis: A comparative proteomic approach  World J Gastroenterol  16: 30-41 (2010)

 

71) Visich K., Pluth Yeo T. The prophylactic use of probiotics in the prevention of radiation therapy-induced diarrheaClinical Journal of Oncology Nursing Vol.14,N.4 (2009)

 

70)  Reiff, C., Delday  M.,  Rucklidge G., Reid M., Duncan G., Wohlgemuth S. ,Ho¨rmannsperger G., Loh G., Blaut M. Collie-Duguid E., Haller D.and Kelly D. Balancing Inflammatory, Lipid, and Xenobiotic Signaling Pathways by VSL#3, a Biotherapeutic Agent, in the Treatment of Inflammatory Bowel Disease  Inflamm Bowel Dis 11:1721-36 (2009)

 

69) Sood A., Midha V., Makharia GK., Ahuja V., Singal D., Goswami P. and Tandon RK.The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 11:1202-9 (2009)

 

68) Wang X., O’Gorman M. R. G., Bu H.F., Koti V., Zuo  X.-Li, and Tan X-D. Probiotic Preparation VSL#3 Alters the Distribution and Phenotypes of Dendritic Cells within the Intestinal Mucosa in C57BL/10J Mice.  Journal of  Nutrition 139:1-8 (2009)

 

67) Tandon P., Moncrief K., Madsen K., Arrieta M.C., Owen R. J., Bain V.G., Wong W.W., Ma M. M. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int.  Aug;29(7):1110–5  (2009)

 

66) El-Atti S. Abd, Wasicek K., Mark S., Hegazi R. Use of Probiotics in the management of chemotherapy- Induced Diarrhea: A Case Study.  J Parenter Enteral Nutr. 33:569-70 (2009)

 

65) Mastrangeli G, Corinti S, Butteroni C, Afferni C, Bonura A, Boirivant M, Colombo P, Di Felice G. Effects of live and inactivated VSL#3 probiotic preparations in the modulation of in vitro and in vivo allergen-induced Th2 responses Arch of Int Allergy and Immunology  150:133–143 ( 2009)

 

64) Hörmannsperger G, Clavel T, Hoffmann M, Reiff  C, Kelly D, Loh G, Blaut M, Hölzlwimmer G, Laschinger M , Haller D. Post-translational Inhibition of IP-10 Secretion in IEC by Probiotic Bacteria: Impact on Chronic Inflammation Secretional Blockade by VSL#3  Plos One 4:e4365 (2009)

 

63)  Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, Bruewer M. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 296:G1140-G1149 (2009).

 

62)  Esposito E., Iacono A., Bianco G., Autore G., Cuzzocrea S., Vajro P., Canini RB., Calignano A., Raso GM., Meli R. Probiotics reduce the inflammatory response induced by a High-Fat Diet in the liver of young rats. J. Nutrition and Disease. May;139(5):905–11 (2009).

 

61)  Arslan H.H., Gulbahar M.Y., Yavuz O., Bozkurt A., Terzi G. Effect of Different Probiotics in Indomethacin-Induced Inflammatory bowel disease in Rats. Dtsch Tierärztl Wochenschr 116, 11-18 (2009)

 

60)  Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 Probiotic Treatment Attenuates Fibrosis Without Changes in Steatohepatitis in a Diet-Induced Nonalcoholic Steatohepatitis Model in Mice. Hepatology 49: 989-997 (2009)

 

59)  Huynh Hien Q, Jennifer deBruyn, Leluo Guan,  Hugo Diaz,  Meiju Li, Safwat Girgis,  Justine Turner, Richard Fedorak, Karen Madsen. Probiotic Preparation VSL#3 Induces Remission in Children with Mild to Moderate Acute Ulcerative Colitis: A Pilot Study Inflamm Bowel Dis 15: 760-768 (2009)

 

58)  Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano R, Staiano A. Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children with Ulcerative Colitis. Am J Gastroenterology 104:437-443 (2009)

 

57)  Otte JM, Rudja MN, Brand S, Ilka W, Wolfgang E. Schmidt, Schmitz F. Probiotics Regulate the Expression of COX-2 in Intestinal Epithelial Cells  Nutrition and Cancer 61: 103-113 (2009)

 

56) Harding S.V., Fraser K.G., Wykes L.J. Probiotics stimulate liver and plasma protein synthesis in piglets with dextran Sulfate-Induced Colitis and macronutrient restriction. The Journal of Nutrition 138:2129-2135 (2008).

 

55) Kotka M., Lieden A., Petterson S., Trinchieri V., Masci A., D’Amato M. Solute Carriers (SLC) in inflammatory Bowel Disease. A potential target of probiotics? J Clin Gastroenterol Vol 42 Supp.3 (2008)

 

54) Dubey AP. et al.  Use of VSL#3® (a new high concentration probiotic mixture) in the treatment of childhood diarrhea with specific reference to Rotavirus Diarrhea J Clin Gastroenterol. 42 Suppl 3 Pt 1:S126-9 (2008)

 

53) Ma X, Hua J, Li Z  Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells  Journal of Hepatology 49:821-30 (2008)

 

52)  Soo I, Madsen KL, Qassim T, Sydora BC, Sherbaniuk R, Cinque B, Di Marzio L, Cifone MG, De Simone C, Fedorak RN VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation  Can J Gastroenterol 22:237-242 (2008)

 

51)  Schlee M, Harder J, Köten B, Stange EF, Wehkamp J, Fellermann K  Probiotic lactobacilli and VSL#3 induce enterocyte b-defensin 2  Clin Experim Immunol 151:528-35 (2008)

 

50)  Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo D, Boirivant M  Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells  Inflamm Bowel Dis 14:662-668 (2008)

 

49) Mc Nally A., BS, LTC George H. Cummings, Peter R. Mc Nally, DO, FACG, FACP A case of recurrent pouchitis successfully managed with a Probiotic, VSL#3 Visible Human Journal of Endoscopy Vol. 6 Issue 1 (2007)

 

48)  Fitzpatrick LR, Hertzog KL, Quatse AL, Koltun WA, Small JS, Vrana K  Effects of the probiotic formulation VSL#3 on colitis in weanling rats  J Pediatric Gastroenterology and Nutrition 44:561-570 (2007)

 

47)  Bowen JM, Stringer AM, Gibson RJ, Yeoh ASJ, Hannam S, Keefe DMK  VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss  Cancer Biol Ther 6:1-6 (2007)

 

46)  Ewaschuk J, Endersby R, Thiel D, Diaz H, Backer J, Mang M, Churchill T, Madsen K Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis   Hepatology 46(3):841–50 (2007)

 

45)  Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon   Int J Colorectal Dis  22:1103-8 (2007)

 

44)  Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, Brigidi P, Vitali B, Straforini G, Campieri M  High-dose probiotics for the treatment of active pouchitis  Dis Colon Rectum 50(12):2075-84 (2007)

 

43)  Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, Famularo  Use of probiotics for prevention of radiation-induced diarrhea   World J Gastroenterol 13:912-915 (2007)

 

42)  Alberda C, Gramlich L, Meddings J, Field C, McCargar L, Kutsogiannis D, Fedorak R, Madsen K Effects of probiotic therapy critically ill patients: a randomized, double-blind, placebo-controlled trial   Am J Clin Nutr 85:816-23 (2007)

 

41) De Angelis M, Rizzello CG, Scala E, De Simone C, Farris GA, Turrini F, Gobbetti M Probiotic preparation has the capacity to hydrolyze proteins responsible for wheat allergy  J Food Prot 70:135-144 (2007)

 

40) Caballero-Franco C, Keller K, De Simone C, Chadee K  The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells  Am J Physiol Gastrointest Liver Physiol 292:G315-22 (2007)

 

39) Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SHE, Schmidt-Ullrich R, Steinhoff U  Proteasome-mediated degradation of IκBα and processing of p105 in Crohn’s disease and ulcerative colitis  J Clin Invest 116:3195-203 (2006)

 

38) Massi M, Ioan P, Budriesi R, Chiarini C, Vitali B, Lammers KM, Gionchetti P, Campieri M, Lembo A, Brigidi P  Effects of probiotic bacteria on gastrointestinal motility in Guinea-pig isolated tissue World J Gastroenterol 12:5987-94 (2006)

 

37) Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, Caramelli E, Gionchetti P, Schrezenmeir J, Foelsch UR, Schreiber S, Campieri M  Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells World J Gastroenterol 12:5978-86 (2006)

 

36) Ewaschuk JB, Walker JW, Diaz H, Madsen KL.  Bioproduction of conjugated linoleic Acid by probiotic bacteria occurs in vitro and in vivo in mice.  J Nutr  136(6):1483-7 (2006)

 

35) Kuehbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, Gionchetti P, Blaut M, Campieri M, Folsch UR, Kamm MA, Shreiber S.  Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis  Gut  55:833-41 (2006)

 

34)  Gaudier E, Michel C, Segain JP, Cherbut C, Hoebler C.  The VSL#3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice  J Nutr 135:2753-61 (2005)

 

33) Linsalata M, Russo F, Berloco P, Valentini AM, Caruso ML, De Simone C, Barone M, Polimeno L, Di Leo A.  Effects of probiotic bacteria (VSL#3) on the poliamine biosynthesis and cell proliferation of normal colonic mucosa of rats  In Vivo 19:989-996 (2005)

 

32) De Angelis M, Rizzello CG, Fasano A, Clemente MG, De Simone C, Silano M, De Vincenzi M, Losito I, Gobbetti M.  VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue  BBA 1762:80-93 (2005)

 

31)  Karimi O, Pena AS, van Bodegraven AA. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn’s disease: A pilot study.  Drugs Today  41:453-9 (2005)

 

30)  Loguercio C, Federico A, Tuccillo C, Terracciano F, D’Auria M V, De Simone C, Del Vecchio Blanco C.  Beneficial effects of a probiotic VSL#3 on Parameters of liver dysfunction in chronic liver disease.  J Clin Gastroenterol 39:540-3 (2005)

 

29) Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB, Ferretti E, Gulino A, Grasso F, De Simone C, Di Mario U, Falorni A, Boirivant M, Dotta F.  Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse.  Diabetologia 48:1565-75 (2005)

 

28) Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G & Zinsmeister AR.  A randomized controlled trial of probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil  17:1–10 (2005)

 

27) Tursi A., Brandimante G, Giorgetti GM, Elisei M.  Beclometasone Diproprionate Plus VSL#3 for the Treatment of Mild to Moderate Diverticular Colitis: An Open Pilot Study.  J Clin Gastroenterol  39:644-5 (2005)

 

26)  Bibiloni R., Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, DeSimone C, Sartor RB.  VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis.  Am J Gastroenterol 100:1539-46 (2005)

 

25) Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M.  Probiotics Ameliorate Recurrent Th1-Mediated Murine Colitis by Inducing IL-10 and IL-10-Dependent TGF-ß-Bearing Regulatory Cells. J Immunol  174:3237-46 (2005)

 

24) Tursi A., Brandimarte G, Giorgetti GM, Forti G, Mondeo ME, Gigliobianco A.  Low dose balsalazide plus a high potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild to moderate ulcerative colitis.  Med Sci Monit 10:PI126-131 (2004)

 

23) Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Yun Tao, De Simone C, Chang EB.  Probiotics inhibit nuclear factor kB and induce heat shock proteins in colonic epithelial cells through Proteasome inhibition.  Gastroenterology 127:1474-1487 (2004)

 

22) Hart AL, Lammers K, Brigidi P,Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm MA, Knight SC, Stagg AJ.   Modulation of human dendritic cell phenotype and function by probiotic bacteria.  Gut  53:1602-1609 (2004)

 

21) Drakes M, Blanchard T, Czinn S.  Bacterial probiotic modulation of dendritic cells.  Infect Immun 72:3299-309 (2004)

 

20) Jijon H, Backer J, Diaz H, Yeung H, Thiel D, Mc Kaigney C, De Simone C, Madsen K.   DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 126:1358-73 (2004)

 

19) Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms.  Am J Physiol Gastrointest Liver Physiol  286: G613–G626 (2004)

 

18) Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E.  Toll-Like Receptor 9 Signaling Mediates the Anti-inflammatory Effects of Probiotics in Murine Experimental Colitis.  Gastroenterology 126 : 520-528 (2004)

 

17) Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA.  Once Daily High Dose Probiotic Therapy (VSL#3) for Maintaining Remission in Recurrent or Refractory Pouchitis.  Gut  53:108-114 (2004)

 

16) Lammers KM, Brigidi P, Vitali B, Gionchetti P, Rizzello F, Caramelli E, Matteuzzi D, Campieri M.  Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol  38:165-72 (2003)

 

15) Vitali B., Candela M., Matteuzzi D., Brigidi P.,  Quantitative detection of probiotic Bifidobacterium strains in bacterial mixtures by using real-time PCR.   Syst Appl Microbiol 26:269-76 (2003)

 

14) Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G,  Miglioli M, Campieri M.  Prophylaxis of Pouchitis Onset with Probiotic Therapy: a Double-blind, Placebo-Controlled Trial.  Gastroenterology 124:1202-09 (2003)

 

13) Kim HJ, Camilleri M, Mc Kinzie S,  Lempke MB, Burton  DD, Thomforde GM, Zinsmeister AR.  A Randomized, Controlled Trial of a Probiotic, VSL#3, on Gut Transit and Symptoms in Diarrhea-predominant Irritable Bowel Syndrome.

 

12) Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, De Simone C, Song X, Diehl AM. Probiotics and Antibodies to TNF Inhibit Inflammatory Activity and Improve Non-Alcoholic Fatty Liver Disease.   Hepatology  37:343-350 (2003)

 

11) Brigidi P, Swennen E,Vitali B, Rossi M, Matteuzzi D.  PCR Detection of Bifidobacterium Strains and Streptococcus Thermophilus in Feces of Human Subjects after Oral Bacteriotherapy and Yogurt Consumption.   Int J Food Microbiol 81:203-209 (2003)

 

10) Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, Campieri M, Morgenstern S, Rachmilewitz D.  Variable Response to Probiotics in Two Models of Experimental Colitis in Rats.  Inflamm Bowel Dis 8:399-406 (2002)

 

9) Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, De Renzis C,  Prophylaxis of Diarrhoea in Patients Submitted to Radiotherapeutic Treatment on Pelvic District: Personal Experience.   Dig Liver Dis 34:S84-86 (2002)

 

8) Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, De Renzis C.  Prevention of Radiation-Induced Diarrhea With High-Potency Probiotic Preparation.   Am J Gastroenterol. 97:13-15 (2002)

 

7) Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, Kamm M, Brigidi P, Gionchetti P, Campieri M.  Effect of Probiotic Strains on Interleukin 8 Production by HT29/19A Cells.   Am J Gastroenterology  97:1182-1186 (2002)

 

6) Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D.  Effects of Probiotic Administration Upon the Composition and Enzymatic Activity of Human Fecal Microbiota in Patients With Irritable Bowel Syndrome or Functional Diarrhea.   Res Microbiol 152:735-471 (2001)

 

5) Madsen K, Cornish A, Soper P, Mc Kaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C,  Probiotic Bacteria Enhance Murine and Human Intestinal Epithelial Barrier Function.   Gastroenterology 121:580-591 (2001)

 

4) Ulisse S, Gionchetti P, D’Alo` S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C.  Expression of Cytokines, Inducible Nitric Oxide Synthase and Matrix Metalloproteinases in Pouchitis: Effects of Probiotic Treatment.   Am J Gastroenterology 96:2691- 2699 (2001)

 

3) Brigidi P, Vitali B, Swennen E, Altomare L, Rossi M, Matteuzzi D, Specific Detection of Bifidobacterium Strains in a Pharmaceutical Probiotic Product and in Human Feces by Polymerase Chain Reaction.   Syst Appl Microbiol 23:391-399 (2000)

 

2) Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M,  Oral Bacteriotherapy as Maintenance Treatment in Patients With Chronic Pouchitis: a Double Blind, Placebo-Controlled Trial.   Gastroenterology 119:305-309 (2000)

 

1) Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M,  Impact on the Composition of the Faecal Flora by a New Probiotic Preparation: Preliminary Data on Maintenance Treatment of Patients With Ulcerative Colitis.  Aliment Pharmacol Ther 13:1103-1108 (1999)

Pharmabest – tylko probiotyki i preparaty najwyższej jakości